title: Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension.
abstract: Clofibrate, a peroxisome proliferator-activated receptor-alpha (PPAR alpha) agonist, increases renal tubular cytochrome P450 4a (Cyp4a) expression thereby increasing 20-hydroxyeicosatetraenoic acid (20-HETE) production. To determine if clofibrate affects blood pressure regulation we studied mice with DOCA-salt induced hypertension in wild-type and PPAR alpha knockout mice. Wild-type mice treated with DOCA-salt had higher mean arterial pressures and higher cumulative sodium balance, but lower renal 20-HETE production than did vehicle-treated mice. Treating DOCA-salt mice with clofibrate attenuated the increase in mean arterial pressure and cumulative sodium balance while increasing 20-HETE production and renal Cyp4a expression. In contrast the PPAR alpha knockout mice treated with clofibrate and DOCA-salt showed no attenuation in the increase of blood pressure, cumulative sodium balance, renal 20-HETE production or Cyp4a protein expression. Expression of the PPAR alpha protein was greater in proximal tubules than in renal microvessels. Our results show that PPAR alpha pathway induces renal tubular 20-HETE production which affects sodium retention and blood pressure regulation in DOCA-salt-treated mice.
authors.affiliation: Department of Physiology, Medical College of Georgia, Augusta, Georgia 30912, USA.
authors.forename: Yiqiang
authors.initials: Y
authors.lastname: Zhou
authors.forename: Pengcheng
authors.initials: P
authors.lastname: Luo
authors.forename: Hsin-Hsin
authors.initials: HH
authors.lastname: Chang
authors.forename: Hui
authors.initials: H
authors.lastname: Huang
authors.forename: Tianxin
authors.initials: T
authors.lastname: Yang
authors.forename: Zheng
authors.initials: Z
authors.lastname: Dong
authors.forename: Cong-Yi
authors.initials: CY
authors.lastname: Wang
authors.forename: Mong-Heng
authors.initials: MH
authors.lastname: Wang
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D002994:Clofibrate / Q000494:pharmacology*; D042926:Cytochrome P-450 CYP4A; D003900:Desoxycorticosterone / Q000009:adverse effects; D006893:Hydroxyeicosatetraenoic Acids / Q000096:biosynthesis*; D006955:Hypernatremia / Q000188:drug therapy*; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology; D007684:Kidney Tubules / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D047493:PPAR alpha / Q000378:metabolism*; D012965:Sodium Chloride / Q000009:adverse effects
chemical_list: D006893:Hydroxyeicosatetraenoic Acids; D047493:PPAR alpha; D003900:Desoxycorticosterone; D012965:Sodium Chloride; C055987:20-hydroxy-5,8,11,14-eicosatetraenoic acid; D042926:Cytochrome P-450 CYP4A; D002994:Clofibrate